Literature DB >> 18449112

Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma.

Mahnaz SahebJamee1, Mohammad Eslami, Fazele AtarbashiMoghadam, Abdolfattah Sarafnejad.   

Abstract

OBJECTIVES: The aim of this study was to compare the concentration of tumor necrosis factor alpha, interleukin 1 alpha, 6, and 8 in the saliva of oral squamous cell carcinoma patients with control group. STUDY
DESIGN: In this study 18 subjects were involved, nine patients with oral squamous cell carcinomas and nine age-sex-matched healthy individuals that were matched for gingival conditions too. Active dental abscesses, collagen vascular diseases, and infectious diseases during one month before saliva sampling were considered as exclusion criteria. Unstimulated whole saliva was collected and after processing the samples were analyzed by Enzyme Linked Immune Assay.
RESULTS: The concentration of salivary interleukin 6 in oral squamous cell carcinoma patients was higher than control group and it was statistically significant (p < 0.05). The concentration of salivary tumor necrosis factor alpha, interleukin 1 alpha and 8 in case group was higher than control group but it was not statistically significant (p > 0.05).
CONCLUSIONS: These results shows that more studies are needed to accept the utility of these cytokines in predicting or diagnosis of oral squamous cell carcinoma or evaluation of treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449112

Source DB:  PubMed          Journal:  Med Oral Patol Oral Cir Bucal        ISSN: 1698-4447


  34 in total

1.  Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells.

Authors:  Jacqueline A Gasche; Jürgen Hoffmann; C Richard Boland; Ajay Goel
Journal:  Int J Cancer       Date:  2011-01-07       Impact factor: 7.396

2.  Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release.

Authors:  Pooja Sabhachandani; Saheli Sarkar; Seamus Mckenney; Dashnamoorthy Ravi; Andrew M Evens; Tania Konry
Journal:  J Control Release       Date:  2018-12-12       Impact factor: 9.776

Review 3.  Updated overview of current biomarkers in head and neck carcinoma.

Authors:  Kiran Dahiya; Rakesh Dhankhar
Journal:  World J Methodol       Date:  2016-03-26

4.  Salivary enzymes and flow rate: Markers of peptic ulcer.

Authors:  Moslem Boghori; Mahmoudreza Aghamaali; Reyhaneh Sariri; Fahime Mohamadpour; Hosein Ghafouri
Journal:  J Oral Biol Craniofac Res       Date:  2014-01-16

5.  Salivary level of interleukin-8 in oral precancer and oral squamous cell carcinoma.

Authors:  Silky Rajesh Punyani; Ramhari Shankarrao Sathawane
Journal:  Clin Oral Investig       Date:  2012-04-18       Impact factor: 3.573

6.  Chronic periodontitis can affect the levels of potential oral cancer salivary mRNA biomarkers.

Authors:  Y-S L Cheng; L Jordan; H-S Chen; D Kang; L Oxford; J Plemons; H Parks; T Rees
Journal:  J Periodontal Res       Date:  2016-08-23       Impact factor: 4.419

7.  Tobacco carcinogen mediated up-regulation of AP-1 dependent pro-angiogenic cytokines in head and neck carcinogenesis.

Authors:  Wade G Swenson; Beverly R K Wuertz; Frank G Ondrey
Journal:  Mol Carcinog       Date:  2011-04-07       Impact factor: 4.784

Review 8.  Salivary Cytokines as Biomarkers for Oral Squamous Cell Carcinoma: A Systematic Review.

Authors:  Elena Ferrari; Margherita E Pezzi; Diana Cassi; Thelma A Pertinhez; Alberto Spisni; Marco Meleti
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

9.  The use of salivary cytokines as a screening tool for oral squamous cell carcinoma : A review of the literature.

Authors:  Tarig A Osman; Daniela E Costea; Anne C Johannessen
Journal:  J Oral Maxillofac Pathol       Date:  2012-05

10.  Gα₁₂ drives invasion of oral squamous cell carcinoma through up-regulation of proinflammatory cytokines.

Authors:  Shiou-Ling Jian; Hsin-Yi Hsieh; Chun-Ta Liao; Tzu-Chen Yen; Shu-Wei Nien; Ann-Joy Cheng; Jyh-Lyh Juang
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.